MRPL33

Across TCGA pan-cancer cohorts, MRPL33 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated MRPL33 data layer compared with 27 for mass-spec protein.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher MRPL33 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated MRPL33 expression acts as an unfavorable survival marker, although some lineages such as COAD and PDAC show a favorable association.

CCRCC, COAD, and PDAC are the cancer types where MRPL33 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	II,III,IV	0.342	0.837	<.001	81	view →
COAD	DFS	Median	II,III,IV	1.000	0.912	.014	36	view →
PDAC	DFS	Tertile	II,III,IV	0.818	0.684	.026	14	view →
HNSC	DFS	Tertile	All	0.623	1.000	.040	6	view →
LSCC	DFS	Median	All	0.397	0.918	.001	5	view →
LUAD	DFS	Tertile	III,IV	0.746	0.281	.023	4	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

MRPL33–CCRCC (DFS)

Open the CCRCC breakdown →